Alphatec Holdings Inc (ATEC)

$12.44

+0.2

(+1.63%)▲

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Alphatec Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 8 quarters, 70.93M → 137.97M (in $), with an average increase of 8.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -42.65M → -49.07M (in $), with an average decrease of 15.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 43.4% return, outperforming this stock by 61.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 73.3% return, outperforming this stock by 99.6%

Performance

  • $12.24
    $12.68
    $12.44
    downward going graph

    1.61%

    Downside

    Day's Volatility :3.47%

    Upside

    1.89%

    downward going graph
  • $8.66
    $19.14
    $12.44
    downward going graph

    30.39%

    Downside

    52 Weeks Volatility :54.75%

    Upside

    35.01%

    downward going graph

Returns

PeriodAlphatec Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
-24.68%
0.5%
0.0%
6 Months
24.39%
11.7%
0.0%
1 Year
-17.74%
6.2%
2.2%
3 Years
-26.31%
13.5%
-23.0%

Highlights

Market Capitalization
1.8B
Book Value
$0.56
Earnings Per Share (EPS)
-1.54
PEG Ratio
0.0
Wall Street Target Price
23.41
Profit Margin
-38.7%
Operating Margin TTM
-25.4%
Return On Assets TTM
-13.98%
Return On Equity TTM
-411.75%
Revenue TTM
482.3M
Revenue Per Share TTM
3.98
Quarterly Revenue Growth YOY
30.2%
Gross Profit TTM
233.1M
EBITDA
-92.1M
Diluted Eps TTM
-1.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.09
EPS Estimate Next Year
-0.76
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Alphatec Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
14
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 88.18%

Current $12.44
Target $23.41

Company Financials

FY18Y/Y Change
Revenue
91.7M
↓ 9.87%
Net Income
-29.0M
↑ 1163.08%
Net Profit Margin
-31.6%
↓ 29.35%
FY19Y/Y Change
Revenue
113.4M
↑ 23.7%
Net Income
-56.9M
↑ 96.38%
Net Profit Margin
-50.17%
↓ 18.57%
FY20Y/Y Change
Revenue
144.9M
↑ 27.71%
Net Income
-79.0M
↑ 38.82%
Net Profit Margin
-54.53%
↓ 4.36%
FY21Y/Y Change
Revenue
243.2M
↑ 67.89%
Net Income
-144.3M
↑ 82.71%
Net Profit Margin
-59.34%
↓ 4.81%
FY22Y/Y Change
Revenue
350.9M
↑ 44.26%
Net Income
-152.1M
↑ 5.42%
Net Profit Margin
-43.36%
↑ 15.98%
FY23Y/Y Change
Revenue
482.3M
↑ 37.45%
Net Income
-186.6M
↑ 22.67%
Net Profit Margin
-38.7%
↑ 4.66%
Q3 FY22Q/Q Change
Revenue
89.8M
↑ 6.76%
Net Income
-37.0M
↓ 0.86%
Net Profit Margin
-41.18%
↑ 3.17%
Q4 FY22Q/Q Change
Revenue
105.9M
↑ 17.93%
Net Income
-35.0M
↓ 5.44%
Net Profit Margin
-33.02%
↑ 8.16%
Q1 FY23Q/Q Change
Revenue
109.1M
↑ 2.99%
Net Income
-43.5M
↑ 24.42%
Net Profit Margin
-39.89%
↓ 6.87%
Q2 FY23Q/Q Change
Revenue
116.9M
↑ 7.16%
Net Income
-51.4M
↑ 18.03%
Net Profit Margin
-43.94%
↓ 4.05%
Q3 FY23Q/Q Change
Revenue
118.3M
↑ 1.15%
Net Income
-42.7M
↓ 16.98%
Net Profit Margin
-36.07%
↑ 7.87%
Q4 FY23Q/Q Change
Revenue
138.0M
↑ 16.66%
Net Income
-49.1M
↑ 15.06%
Net Profit Margin
-35.57%
↑ 0.5%
FY18Y/Y Change
Total Assets
129.5M
↑ 52.94%
Total Liabilities
111.9M
↑ 0.53%
FY19Y/Y Change
Total Assets
169.9M
↑ 31.26%
Total Liabilities
126.3M
↑ 12.88%
FY20Y/Y Change
Total Assets
261.2M
↑ 53.71%
Total Liabilities
131.3M
↑ 3.98%
FY21Y/Y Change
Total Assets
572.1M
↑ 118.99%
Total Liabilities
492.6M
↑ 275.07%
FY22Y/Y Change
Total Assets
513.4M
↓ 10.26%
Total Liabilities
550.1M
↑ 11.66%
FY23Y/Y Change
Total Assets
805.2M
↑ 56.85%
Total Liabilities
703.5M
↑ 27.89%
Q3 FY22Q/Q Change
Total Assets
516.3M
↑ 0.85%
Total Liabilities
538.9M
↑ 7.47%
Q4 FY22Q/Q Change
Total Assets
513.4M
↓ 0.56%
Total Liabilities
550.1M
↑ 2.09%
Q1 FY23Q/Q Change
Total Assets
569.7M
↑ 10.97%
Total Liabilities
628.1M
↑ 14.17%
Q2 FY23Q/Q Change
Total Assets
628.2M
↑ 10.28%
Total Liabilities
656.4M
↑ 4.51%
Q3 FY23Q/Q Change
Total Assets
670.2M
↑ 6.68%
Total Liabilities
714.4M
↑ 8.84%
Q4 FY23Q/Q Change
Total Assets
805.2M
↑ 20.14%
Total Liabilities
703.5M
↓ 1.52%
FY18Y/Y Change
Operating Cash Flow
-25.6M
↑ 193.37%
Investing Cash Flow
-21.7M
↑ 233.63%
Financing Cash Flow
53.9M
↑ 202.37%
FY19Y/Y Change
Operating Cash Flow
-33.1M
↑ 29.34%
Investing Cash Flow
-13.0M
↓ 39.86%
Financing Cash Flow
64.2M
↑ 19.11%
FY20Y/Y Change
Operating Cash Flow
-46.4M
↑ 40.13%
Investing Cash Flow
-23.9M
↑ 83.08%
Financing Cash Flow
130.8M
↑ 103.84%
FY21Y/Y Change
Operating Cash Flow
-73.4M
↑ 58.22%
Investing Cash Flow
-157.8M
↑ 561.23%
Financing Cash Flow
312.0M
↑ 138.45%
FY22Y/Y Change
Operating Cash Flow
-75.1M
↑ 2.33%
Investing Cash Flow
-58.3M
↓ 63.06%
Financing Cash Flow
31.2M
↓ 89.99%
Q3 FY22Q/Q Change
Operating Cash Flow
-14.7M
↓ 46.27%
Investing Cash Flow
-15.6M
↑ 8.45%
Financing Cash Flow
29.4M
↓ 1628.76%
Q4 FY22Q/Q Change
Operating Cash Flow
-8.4M
↓ 42.8%
Investing Cash Flow
-14.8M
↓ 5.07%
Financing Cash Flow
1.0M
↓ 96.56%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.3M
↑ 118.06%
Investing Cash Flow
-16.8M
↑ 13.35%
Financing Cash Flow
67.1M
↑ 6524.88%
Q2 FY23Q/Q Change
Operating Cash Flow
-17.9M
↓ 2.47%
Investing Cash Flow
-75.6M
↑ 349.35%
Financing Cash Flow
77.9M
↑ 16.1%

Technicals Summary

Sell

Neutral

Buy

Alphatec Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alphatec Holdings Inc
Alphatec Holdings Inc
-8.72%
24.39%
-17.74%
-26.31%
288.57%
Stryker Corporation
Stryker Corporation
-3.78%
30.39%
12.83%
27.09%
79.07%
Dexcom, Inc.
Dexcom, Inc.
-1.37%
70.19%
10.47%
31.82%
344.58%
Boston Scientific Corp.
Boston Scientific Corp.
7.83%
47.17%
43.37%
73.31%
95.99%
Abbott Laboratories
Abbott Laboratories
-4.16%
13.71%
-1.74%
-12.82%
36.02%
Medtronic Plc
Medtronic Plc
-5.32%
12.62%
-11.92%
-39.09%
-9.27%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alphatec Holdings Inc
Alphatec Holdings Inc
NA
NA
0.0
-1.09
-4.12
-0.14
NA
0.56
Stryker Corporation
Stryker Corporation
40.83
40.83
2.92
11.85
0.18
0.07
0.01
48.92
Dexcom, Inc.
Dexcom, Inc.
102.89
102.89
2.53
1.76
0.26
0.06
NA
5.37
Boston Scientific Corp.
Boston Scientific Corp.
68.14
68.14
1.8
2.25
0.09
0.04
NA
13.16
Abbott Laboratories
Abbott Laboratories
33.3
33.3
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.52
25.52
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alphatec Holdings Inc
Alphatec Holdings Inc
Buy
$1.8B
288.57%
NA
-38.7%
Stryker Corporation
Stryker Corporation
Buy
$128.2B
79.07%
40.83
15.44%
Dexcom, Inc.
Dexcom, Inc.
Buy
$54.6B
344.58%
102.89
14.95%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$107.2B
95.99%
68.14
11.18%
Abbott Laboratories
Abbott Laboratories
Buy
$185.5B
36.02%
33.3
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-9.27%
25.52
13.0%

Institutional Holdings

  • BlackRock Inc

    5.52%

  • First Light Asset Management, LLC

    4.29%

  • Vanguard Group Inc

    3.87%

  • American Century Companies Inc

    2.56%

  • Goldman Sachs Group Inc

    2.08%

  • JPMorgan Chase & Co

    2.01%

Corporate Announcements

  • Alphatec Holdings Inc Earnings

    Alphatec Holdings Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

as a medical technology company, we improve lives by providing innovative spine surgery solutions through our relentless pursuit of superior outcomes. we are dedicated to the design, development, launch and the delivery of spinal fusion products. we seek to accomplish this by working with spine surgeons to design and develop products and systems that address the entire spinal fusion procedure in the most effective and efficient way possible. our product designs and platforms provide innovation through a focus on simplifying procedures for the surgeon with the ultimate objective of superior outcomes. alphatec spine is seeking growth through innovation and continually developing technologies that will have a greater positive impact on patient care and outcomes. please visit our website for more information: www.alphatecspine.com

Organization
Alphatec Holdings Inc
Employees
839
CEO
Mr. Patrick S. Miles
Industry
Health Technology

Discover More

FAQs